Systagenix Reveals New CEO

Ernest Waaser has been appointed CEO and director at Systagenix Wound Management, a UK-based wound care provider. Steve Atkinson, the departing CEO, will continue to work with One Equity Partners as a consultant and advisor on medical device investments. One Equity counts Systagenix—formerly Johnson & Johnson’s wound care business—among its healthcare and medical device portfolio companies.


GATWICK, England– Systagenix Wound Management (Gatwick, UK) today announced the appointment of Ernest Waaser as Chief Executive Officer and a member of the Board of Directors. A veteran medical device industry executive, Waaser was most recently President of Teleflex Medical and previously served as President and Chief Executive Officer of Hill-Rom. He will be located at the company’s global headquarters in Gatwick, UK. He replaces Steve Atkinson, who will continue to work with One Equity Partners as a consultant and advisor on medical device investments.

“We thank Steve Atkinson for his tremendous service over the last three years, and are delighted to have an executive of Ernest’s calibre now joining Systagenix as CEO,” said Board member Chris Ahrens. “His strong track record of growing companies organically and through acquisition, extensive global experience, and broad medical device background is an excellent fit and we look forward to his leadership.”
“I am honoured and excited to be joining Systagenix at this important phase in the company’s development,” said Waaser. “With a singular focus on wound care represented by the unique Let’s Heal® system, an impressive and truly innovative pipeline of new Systagenix products, lead by the imminent WOUNDCHEK™ diagnostics franchise, and a talented group of employees around the world, Systagenix is well positioned to achieve its vision of becoming the world’s strongest and most admired wound care company.”
Home of the Let’s Heal® system, and focused 100% in wound care, Systagenix is a leading global supplier of advanced wound care solutions. More recently, the company announced its commitment to be the first to enter the field of wound diagnostics, by introducing the first point of care test to detect elevated levels of protease activity, which is a key marker for wound healing, as highlighted by several published articles and international consensus documents. Once available, this will be the entry point of the Let’s Heal® system, making it a unique system within the world of wound care.
Formed via the acquisition of Johnson & Johnson’s advanced wound care business in 2008, the company supplies over 20 million wound dressings per month into over 100 countries worldwide for use in treating hard-to-heal acute and chronic wounds. Its leading edge product portfolio includes ADAPTIC TOUCH®, TIELLE®, SILVERCEL® NON-ADHERENT, ACTISORB®, INADINE®, PROMOGRAN®, and PROMOGRAN PRISMA®.